Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Non-randomized comparative studies are often used to compare treatment effects between an investigational product and a control when randomization is not feasible or difficult in practice. A typical situation is that the product is investigated in a single-arm study, and the control data are collected in an external data source. For such a situation, we propose an alternative approach to draw inference on the treatment effect difference. First, a potential outcome model (POM) for the outcome under control treatment is built based on the external control data source. Next, the POM is utilized to impute outcomes of subjects in the single-arm study as if they were treated with the control treatment. Then the inference on the treatment effect difference can be made by comparing imputed outcomes (for the control) and observed outcomes (for the investigational product). The main purpose of this paper is to provide a proof of concept regarding how to perform inference on the treatment effect between the investigational product and the control under this scenario. We illustrate our approach by assuming the endpoint to follow a normal distribution and the POM to be a linear regression model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43441-025-00839-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial.
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.
In recent years, several biologics have been introduced into hospitals and clinics as alternatives to surgery and/or topical/oral cortisone therapy in patients with severe refractory chronic rhinosinusitis with polyps (CRSwNP). Advances in understanding the pathophysiology of CRSwNP in relation to the predominant type 2 endotype have also paved the way for understanding possible overlaps with hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA). In this article, we present the biologic treatment options currently approved in Germany for the treatment of severe CRSwNP - dupilumab, omalizumab and mepolizumab - together with guidance on practical management including side effects for the indication of CRSwNP.
View Article and Find Full Text PDFSemaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.
JAMA Psychiatry
September 2025
Department of Endocrinology, Odense University Hospital, Odense, Denmark.
Importance: Patients with schizophrenia have reduced life expectancy due to cardiovascular disease and obesity-related type 2 diabetes, exacerbated by second-generation antipsychotic (SGA) medication. Existing interventions have shown limited effect.
Objectives: To assess the effect of the once-weekly glucagon-like peptide-1 receptor agonist semaglutide in SGA-treated adults (aged 18-60 years) with schizophrenia, prediabetes (glycosylated hemoglobin A1c [HbA1c], 5.
Chemotherapy Orders Team: A non-traditional operational and clinical support team enhancing order set development and implementation.
J Oncol Pharm Pract
September 2025
Department of Pharmacy, University of Michigan Health - Academic Medical Center, Ann Arbor, MI, USA.
ObjectiveOncology treatment regimens require increasing information technology (IT) integration in health systems to enhance delivery and safety, however, this creates a burden on medical teams and clinical pharmacists to manage. This primer introduces the University of Michigan Health Academic Medical Center's (UMH-AMC) response to this need with the Chemotherapy Orders Team (COT).SummaryThe COT includes five clinical oncology pharmacy generalists with a split full-time equivalent (FTE) appointment in COT-based activities and staffing in infusion.
View Article and Find Full Text PDFPaternal prepubertal passive smoke exposure is related to impaired lung function trajectories from childhood to middle age in their offspring.
Thorax
September 2025
Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Introduction: Paternal prepubertal passive smoke exposure may increase the risk of childhood asthma. However, its association with impaired lung function trajectories at risk of chronic obstructive pulmonary disease in offspring was not investigated. We assessed the association between paternal prepubertal passive smoke exposure and lung function from childhood to middle age in their offspring.
View Article and Find Full Text PDF